Cantor Fitzgerald Weighs in on PACB FY2025 Earnings

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Pacific Biosciences of California in a note issued to investors on Tuesday, February 18th. Cantor Fitzgerald analyst R. Osborn now forecasts that the biotechnology company will post earnings of ($0.68) per share for the year, down from their prior forecast of ($0.62). The consensus estimate for Pacific Biosciences of California’s current full-year earnings is ($0.71) per share.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings data on Thursday, February 13th. The biotechnology company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). Pacific Biosciences of California had a negative net margin of 200.40% and a negative return on equity of 42.89%. The business had revenue of $39.22 million for the quarter, compared to analyst estimates of $39.20 million. During the same period in the prior year, the business posted ($0.27) earnings per share.

A number of other brokerages have also commented on PACB. Piper Sandler restated a “neutral” rating and set a $2.00 target price (down previously from $2.50) on shares of Pacific Biosciences of California in a report on Thursday. StockNews.com raised Pacific Biosciences of California to a “sell” rating in a research report on Friday, February 14th. Stephens reaffirmed an “overweight” rating and set a $2.50 target price on shares of Pacific Biosciences of California in a report on Friday, February 14th. Scotiabank reduced their price target on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating for the company in a research note on Monday, November 11th. Finally, The Goldman Sachs Group decreased their target price on shares of Pacific Biosciences of California from $1.75 to $1.50 and set a “neutral” rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $2.79.

Pacific Biosciences of California Stock Down 7.3 %

NASDAQ:PACB opened at $1.64 on Thursday. The company has a current ratio of 9.74, a quick ratio of 8.64 and a debt-to-equity ratio of 1.97. The stock has a 50-day moving average price of $1.77 and a two-hundred day moving average price of $1.79. Pacific Biosciences of California has a 1 year low of $1.16 and a 1 year high of $6.09. The stock has a market cap of $449.13 million, a price-to-earnings ratio of -1.00 and a beta of 1.92.

Insider Activity

In related news, insider Michele Farmer sold 24,349 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $1.88, for a total value of $45,776.12. Following the transaction, the insider now owns 187,592 shares in the company, valued at $352,672.96. The trade was a 11.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Oene Mark Van sold 34,405 shares of Pacific Biosciences of California stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $2.03, for a total value of $69,842.15. Following the completion of the transaction, the insider now directly owns 1,597,454 shares of the company’s stock, valued at approximately $3,242,831.62. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. PCA Investment Advisory Services Inc. increased its holdings in Pacific Biosciences of California by 50.0% during the 4th quarter. PCA Investment Advisory Services Inc. now owns 15,000 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 5,000 shares in the last quarter. Atom Investors LP bought a new position in shares of Pacific Biosciences of California during the 3rd quarter worth $30,000. Atria Investments Inc boosted its position in Pacific Biosciences of California by 85.7% during the third quarter. Atria Investments Inc now owns 21,968 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 10,138 shares during the period. Centiva Capital LP bought a new position in Pacific Biosciences of California in the 3rd quarter worth approximately $40,000. Finally, First Trust Advisors LP bought a new position in shares of Pacific Biosciences of California in the fourth quarter worth $42,000.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.